Advanced Enzyme FY26: Record Revenue, India Momentum, and a Bigger R&D Push

Revenue from operations was INR 2,034 million, EBITDA was INR 632 million, and PAT was INR 453 million (PAT before minority), as per the presentation.

FY26 revenue from operations was INR 7,458 million, EBITDA was INR 2,291 million, and PAT was INR 1,736 million (PAT before minority), as per the presentation.

Segments shown are Human Nutrition (63% of sales), Animal Nutrition (13%), Industrial Bio-processing (16%), and Specialized Manufacturing (9%) for FY26.

In Q4 FY26, India was INR 1,061 million (+51% YoY), Americas INR 573 million (-11%), Europe INR 95 million (-7%), Asia excluding India INR 249 million (+38%), and Rest of World INR 57 million (+44%).

Management said the new R&D center in Nashik is expected to be fully operational in the latter half of the fiscal year, and the CFO indicated R&D revenue expenditure could rise by about INR 50 million.

Management said they filed two food enzyme dossiers with EFSA and three dossiers with the US FDA during the year, and they are anticipating European approval for anti-inflammatory products filed two years earlier.